In December 2019, a novel coronavirus, now officially named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified in Wuhan China, which caused the outbreak of a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19). Signs and symptoms of COVID-19 may occur 2 to 14 days after infection, which include fever, cough, shortness of breath or difficulties in breathing, muscle pain and tiredness. In severe cases, the infection can further lead to pneumonia, severe acute respiratory syndrome (SARS), kidney failure and death.
Biosensis offers research reagents addressing the urgent need of the research community to understand human immunity, explore treatment options and find potential cures. Biosensis' SARS-CoV-2 research product portfolio includes ELISA kits, proteins and small molecule inhibitors.